ACE2 and COVID-19: Furthermore, Zoufaly et al. [93], in a case report, showed that the treatment of a 45-year-old woman diagnosed with severe COVID-19 with human recombinant soluble ACE2 (hrsACE2) for 9 days decreased the Ang II level, pro-inflammatory interleukins such as IL-6 and IL-8, inflammation marker ferritin, and C-reactive protein.